Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children [PDF]
Malaria Journal, 2021 Background RTS,S/AS01, the leading malaria vaccine has been recommended by the WHO for widespread immunization of children at risk. RTS,S/AS01-induced anti-CSP IgG antibodies are associated with the vaccine efficacy. Here, the long-term kinetics of RTS,S/
Robert M. Mugo +8 more
doaj +2 more sources
T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. [PDF]
PLoS ONE, 2011 BackgroundThe Plasmodium falciparum pre-erythrocytic stage candidate vaccine RTS,S is being developed for protection of young children against malaria in sub-Saharan Africa.
Daniel Ansong +28 more
doaj +3 more sources
Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case–control study [PDF]
eLife, 2022 Background: In a phase 3 trial in African infants and children, the RTS,S/AS01 vaccine (GSK) showed moderate efficacy against clinical malaria. We sought to further understand RTS,S/AS01-induced immune responses associated with vaccine protection ...
Gemma Moncunill +26 more
doaj +2 more sources
Frontiers in Big Data, 2021 RTS,S/AS01 (GSK) is the world’s first malaria vaccine. However, despite initial efficacy of almost 70% over the first 6 months of follow-up, efficacy waned over time.
William Chad Young +36 more
doaj +2 more sources
npj Vaccines, 2023 Respiratory syncytial virus (RSV) causes a high disease burden in older adults. An effective vaccine for this RSV-primed population may need to boost/elicit robust RSV-neutralizing antibody responses and recall/induce RSV-specific T cell responses.
Badiaa Bouzya +10 more
doaj +2 more sources
Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections [PDF]
npj VaccinesAS01-adjuvanted shingles (herpes zoster) vaccination is associated with a lower risk of dementia, but the underlying mechanisms are unclear. In propensity-score matched cohort studies with 436,788 individuals, both the AS01-adjuvanted shingles and ...
Maxime Taquet +2 more
doaj +2 more sources
npj Vaccines, 2023 Mouse models are useful for the early down-selection of malaria vaccine candidates. The Walter Reed Army Institute of Research has optimized a transgenic Plasmodium berghei sporozoite challenge model to compare the efficacy of Plasmodium falciparum ...
Christopher J. Genito +7 more
doaj +2 more sources
Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status [PDF]
BMC Public Health, 2021 Background In the phase III RTS,S /AS01 trial, significant heterogeneity in efficacy of the vaccine across study sites was seen. Question on whether variations in socio - economic status (SES) of participant contributed to the heterogeinity of the ...
Stephaney Gyaase +5 more
doaj +2 more sources
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. [PDF]
PLoS ONE, 2009 The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen.
Bertrand Lell +15 more
doaj +2 more sources
Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation [PDF]
BMJ Global HealthIn October 2021, the WHO recommended the world’s first malaria vaccine—RTS,S/AS01—to prevent malaria in children living in areas with moderate-to-high transmission in sub-Saharan Africa (SSA).
Feiko O ter Kuile +9 more
doaj +2 more sources